CN115427068A - 奥法妥木单抗治疗MS同时维持血清IgG - Google Patents

奥法妥木单抗治疗MS同时维持血清IgG Download PDF

Info

Publication number
CN115427068A
CN115427068A CN202180027438.7A CN202180027438A CN115427068A CN 115427068 A CN115427068 A CN 115427068A CN 202180027438 A CN202180027438 A CN 202180027438A CN 115427068 A CN115427068 A CN 115427068A
Authority
CN
China
Prior art keywords
ofatumumab
cell
treatment
patients
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027438.7A
Other languages
English (en)
Chinese (zh)
Inventor
R·平吉利
M·梅尔舍姆克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN115427068A publication Critical patent/CN115427068A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180027438.7A 2020-04-09 2021-04-09 奥法妥木单抗治疗MS同时维持血清IgG Pending CN115427068A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20169007.0 2020-04-09
EP20169007 2020-04-09
EP20176057 2020-05-22
EP20176057.6 2020-05-22
US202063076628P 2020-09-10 2020-09-10
US63/076,628 2020-09-10
US202163166054P 2021-03-25 2021-03-25
US63/166,054 2021-03-25
PCT/EP2021/059285 WO2021204994A1 (en) 2020-04-09 2021-04-09 Ofatumumab for treating ms while maintaining serum igg

Publications (1)

Publication Number Publication Date
CN115427068A true CN115427068A (zh) 2022-12-02

Family

ID=75362645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027438.7A Pending CN115427068A (zh) 2020-04-09 2021-04-09 奥法妥木单抗治疗MS同时维持血清IgG

Country Status (12)

Country Link
US (1) US20230151106A1 (https=)
EP (3) EP4707302A2 (https=)
JP (2) JP7794757B2 (https=)
KR (1) KR20220166827A (https=)
CN (1) CN115427068A (https=)
AU (1) AU2021253674A1 (https=)
BR (1) BR112022019038A2 (https=)
CA (1) CA3176574A1 (https=)
DE (1) DE202021004005U1 (https=)
IL (1) IL296701A (https=)
MX (1) MX2022012600A (https=)
WO (1) WO2021204994A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641965A (zh) * 2016-08-15 2019-04-16 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2012018704A1 (en) * 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2748198A2 (en) * 2011-09-27 2014-07-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
MX2022003010A (es) * 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
US20240343821A1 (en) * 2021-08-16 2024-10-17 Novartis Ag Ofatumumab for treating pediatric ms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641965A (zh) * 2016-08-15 2019-04-16 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GELFAND ET AL.: "Ocrelizumab and Other CD20+ B-Cell-Depleting Therapiesin Multiple Sclerosis", NEUROTHERAPEUTICS, vol. 14, no. 4, 10 July 2017 (2017-07-10), pages 836 - 838 *

Also Published As

Publication number Publication date
JP2023521754A (ja) 2023-05-25
EP4682171A2 (en) 2026-01-21
DE202021004005U1 (de) 2022-05-06
BR112022019038A2 (pt) 2022-11-01
EP4682171A3 (en) 2026-05-06
CA3176574A1 (en) 2021-10-14
US20230151106A1 (en) 2023-05-18
WO2021204994A1 (en) 2021-10-14
EP4132564A1 (en) 2023-02-15
JP7794757B2 (ja) 2026-01-06
MX2022012600A (es) 2023-02-15
EP4707302A2 (en) 2026-03-11
KR20220166827A (ko) 2022-12-19
IL296701A (en) 2022-11-01
JP2026009900A (ja) 2026-01-21
AU2021253674A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP2026009900A (ja) 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ
EP3864053B1 (en) Treatment of rms by switching therapy
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
US20240228647A1 (en) Ofatumumab for treating multiple sclerosis in asian patients
JP2021523881A (ja) リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法
WO2017221174A1 (en) Methods of treating vitiligo using interleukin-17 (il-17) antibodies
TW202300523A (zh) 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB)
BR122024017958A2 (pt) Usos de ofatumumab para tratamento de esclerose múltipla (em) enquanto mantém a igg sérica
US20230235041A1 (en) Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
CN117015397A (zh) 用于治疗狼疮的方法和组合物
HK40051003B (en) Treatment of rms by switching therapy
HK40051003A (en) Treatment of rms by switching therapy
CN121843712A (zh) 用于治疗多发性硬化症的组合物和方法
WO2021111377A2 (en) Methods of treating lichen planus using interleukin-17 (il-17) antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination